The Enterprise Value as of December 2025 (TTM) for Prostatype Genomics AB (publ) (PROGEN.ST) is 7.83M

According to Prostatype Genomics AB (publ)’s latest financial reports and current stock price. The company's current Enterprise Value is 7.83M. This represents a change of -62.16% compared to the average of 20.70M of the last 4 quarters.

Prostatype Genomics AB (publ) (PROGEN.ST) Historical Enterprise Value (quarterly & annually)

How has PROGEN.ST Enterprise Value performed in the past?

The mean historical Enterprise Value of Prostatype Genomics AB (publ) over the last ten years is 1.61B. The current 7.83M Enterprise Value has changed -51.22% with respect to the historical average. Over the past ten years (40 quarters), PROGEN.ST's Enterprise Value was at its highest in in the June 2021 quarter at 6.35B. The Enterprise Value was at its lowest in in the June 2025 quarter at 4.42M.

Prostatype Genomics AB (publ) (PROGEN.ST) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Prostatype Genomics AB (publ) Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Prostatype Genomics AB (publ) (PROGEN.ST) Average Enterprise Value

How has PROGEN.ST Enterprise Value performed in the past?

The current Enterprise Value of Prostatype Genomics AB (publ) (PROGEN.ST) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Prostatype Genomics AB (publ) (PROGEN.ST) Enterprise Value vs. Peers

How is PROGEN.ST’s Enterprise Value compared to its peers?

Prostatype Genomics AB (publ)’s Enterprise Value is less than Spermosens AB (10.28M), less than Qlife Holding AB (publ) (25.21M), greater than Episurf Medical AB (publ) (5.93M), less than ODI Pharma AB (29.49M), less than Aptahem AB (publ) (15.20M), less than Aino Health AB (publ) (38.70M), less than Fluicell AB (publ) (10.07M), less than 2cureX AB (publ) (18.71M), greater than Chordate Medical Holding AB (publ) (-2753550.00), less than Stayble Therapeutics AB (publ) (13.43M),

Build a custom stock screener for Prostatype Genomics AB (publ) (PROGEN.ST) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prostatype Genomics AB (publ) using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prostatype Genomics AB (publ) (PROGEN.ST) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prostatype Genomics AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.